MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
107.40
+2.73
+2.60%
After Hours: 105.26 -2.14 -1.99% 18:02 08/12 EDT
OPEN
106.57
PREV CLOSE
104.68
HIGH
109.42
LOW
104.59
VOLUME
945.27K
TURNOVER
--
52 WEEK HIGH
109.42
52 WEEK LOW
12.84
MARKET CAP
7.11B
P/E (TTM)
-44.9466
1D
5D
1M
3M
1Y
5Y
1D
Oruka Therapeutics (ORKA) Has a New Rating from Wedbush
TipRanks · 18h ago
Analysts Are Bullish on These Healthcare Stocks: Oruka Therapeutics (ORKA), Zura Bio (ZURA)
TipRanks · 1d ago
Jefferies Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
TipRanks · 1d ago
Oruka Therapeutics Price Target Maintained With a $200.00/Share by Guggenheim
Dow Jones · 1d ago
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Benzinga · 1d ago
Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush
Dow Jones · 1d ago
Oruka Therapeutics (ORKA) Receives a Buy from Piper Sandler
TipRanks · 1d ago
Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target
TipRanks · 1d ago
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.